Laboratorios Richmond SACIF (RICH) - Total Liabilities
Based on the latest financial reports, Laboratorios Richmond SACIF (RICH) has total liabilities worth AR$282.24 Billion ARS (≈ $204.23 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Laboratorios Richmond SACIF - Total Liabilities Trend (2006–2024)
This chart illustrates how Laboratorios Richmond SACIF's total liabilities have evolved over time, based on quarterly financial data. See Laboratorios Richmond SACIF short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Laboratorios Richmond SACIF Competitors by Total Liabilities
The table below lists competitors of Laboratorios Richmond SACIF ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Se Gyung Hi Tech Co.Ltd
KQ:148150
|
Korea | ₩111.76 Billion |
|
LIG-ES SPAC
KQ:220260
|
Korea | ₩54.42 Billion |
|
Deutsch Motors Inc
KQ:067990
|
Korea | ₩1.30 Trillion |
|
Nurol Gayrimenkul Yatirim Ortakligi AS
IS:NUGYO
|
Turkey | TL394.10 Million |
|
Superior Plating Technology Co Ltd
TWO:8431
|
Taiwan | NT$455.57 Million |
|
Nanexa AB
ST:NANEXA
|
Sweden | Skr39.57 Million |
|
Datagate Bilgisayar Malzemeleri Ticaret AS
IS:DGATE
|
Turkey | TL5.00 Billion |
|
PolyPid
NASDAQ:PYPD
|
USA | $11.33 Million |
Liability Composition Analysis (2006–2024)
This chart breaks down Laboratorios Richmond SACIF's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RICH stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.96 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.80 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Laboratorios Richmond SACIF's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Laboratorios Richmond SACIF (2006–2024)
The table below shows the annual total liabilities of Laboratorios Richmond SACIF from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | AR$194.80 Billion ≈ $140.96 Million |
-32.20% |
| 2023-12-31 | AR$287.34 Billion ≈ $207.92 Million |
+842.02% |
| 2022-12-31 | AR$30.50 Billion ≈ $22.07 Million |
+50.13% |
| 2021-12-31 | AR$20.32 Billion ≈ $14.70 Million |
+327.48% |
| 2020-12-31 | AR$4.75 Billion ≈ $3.44 Million |
+56.62% |
| 2019-12-31 | AR$3.03 Billion ≈ $2.20 Million |
+90.35% |
| 2018-12-31 | AR$1.59 Billion ≈ $1.15 Million |
+84.39% |
| 2017-12-31 | AR$864.59 Million ≈ $625.62K |
+28.72% |
| 2016-12-31 | AR$671.67 Million ≈ $486.03K |
+53.80% |
| 2015-12-31 | AR$436.71 Million ≈ $316.01K |
+49.23% |
| 2014-12-31 | AR$292.64 Million ≈ $211.76K |
+49.05% |
| 2013-12-31 | AR$196.34 Million ≈ $142.07K |
+9.72% |
| 2012-12-31 | AR$178.94 Million ≈ $129.48K |
+64.29% |
| 2011-12-31 | AR$108.92 Million ≈ $78.82K |
+19.74% |
| 2010-12-31 | AR$90.96 Million ≈ $65.82K |
+22.74% |
| 2009-12-31 | AR$74.11 Million ≈ $53.62K |
+3.88% |
| 2008-12-31 | AR$71.34 Million ≈ $51.62K |
+10.89% |
| 2007-12-31 | AR$64.33 Million ≈ $46.55K |
+32.35% |
| 2006-12-31 | AR$48.61 Million ≈ $35.17K |
-- |
About Laboratorios Richmond SACIF
Laboratorios Richmond S.A.C.I.F., a pharmaceutical company, develops and manufactures pharmaceutical products. It provides antiretroviral products for the treatment of human immunodeficiency virus (HIV); oncology and oncohematology drugs; cardiometabolic drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs … Read more